(COO) The Cooper Companies, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COO) The Cooper Companies, Inc. Bundle
See the Bigger Picture
This The Cooper Companies, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
MiSight 1 day myopia-control lens
Childhood myopia is a fast-growing global market, with about 30% of people already affected and forecasts near 50% by 2050. MiSight 1 day is the first FDA-approved soft lens shown to slow myopia progression, giving CooperVision an early-mover edge. It still needs wider rollout and steady marketing, but the growth runway stays strong.
Biofinity Toric contact lenses
Biofinity Toric serves the large astigmatism market; astigmatism affects about 30% of people, so demand is broad and recurring. Biofinity is a core CooperVision brand with strong practitioner trust and global reach, which supports steady prescription flow. That mix of scale and growth keeps it in the Star quadrant.
Biofinity Multifocal contact lenses
Biofinity Multifocal sits in a premium niche, and rising presbyopia supports demand: the WHO has said 2.2 billion people had near vision impairment in 2025, with aging driving more cases. Cooper Companies can keep this a Star by funding awareness and fitter training, since premium multifocal lenses win on comfort and convenience. CooperVision’s scale and fitting support help defend share as more older adults seek daily-wear upgrades.
Daily disposable silicone hydrogel lenses
Daily disposable silicone hydrogel lenses are a Star in The Cooper Companies, Inc. BCG Matrix because the format is still one of the fastest-growing parts of the contact lens market. CooperVision’s clariti 1 day and MyDay sit right in that demand shift, and the category needs steady promotion, fitting help, and strong retailer shelf space to keep growing.
- Fast-growing one-day lens format
- CooperVision has key brands here
- Support and placement drive share
- Fits a high-growth, high-share profile
In fiscal 2025, The Cooper Companies, Inc. continued to lean on CooperVision as its core growth engine, and daily disposables stay central to that mix. The logic is simple: more first-time wearers want comfort and convenience, and silicone hydrogel one-day lenses answer both.
CooperSurgical fertility consumables and embryo services
CooperSurgical’s fertility consumables and embryo services sit in a recurring-use market, so each IVF cycle drives repeat demand. Global IVF use keeps expanding, and the large installed base in clinics helps CooperSurgical keep winning share. That makes this a Star in the BCG Matrix: high growth and a still-compounding position.
- Repeat clinic demand supports sales
- Installed base lowers switching risk
- Growth still leaves room to gain share
CooperVision’s Myopia and Toric Lenses Power Growth
Stars in The Cooper Companies, Inc. are led by CooperVision’s myopia, daily disposable, and toric lenses: MiSight 1 day targets a market where about 30% of people are affected and near 50% may be by 2050, while astigmatism affects about 30% too. In FY2025, these lines kept growth high as demand shifted to comfort and convenience.
| Star | Key data | Why it fits |
|---|---|---|
| MiSight 1 day | 30% affected; 50% by 2050 | FDA-first mover |
| Biofinity Toric | 30% astigmatism | Large recurring demand |
What is included in the product
Detailed Word Document
BCG Matrix for The Cooper Companies maps its units into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page BCG Matrix for The Cooper Companies, Inc. that quickly spots stars, cash cows, and underperformers.
Reference Sources
Provides a clear source trail for The Cooper Companies, Inc., making the analysis more credible and easier to trust, verify, and act on.
Cash Cows
Biofinity spherical monthly lenses
Biofinity spherical monthly lenses are a mature core franchise inside CooperVision, and they keep producing steady repeat demand. In CooperCompanies' FY2025, net sales were about $4.0 billion, and this brand helps support that cash flow base. Growth is slower than newer lens types, but the monthly category is broad and dependable.
PARAGARD copper IUD
PARAGARD is The Cooper Companies, Inc.’s long-settled U.S. copper IUD, approved for up to 10 years of use and backed by a durable non-hormonal niche. The U.S. IUD category is mature, so growth is limited, but PARAGARD still holds a stable spot in a high-value contraception market. That steady demand and low growth fit a classic cash cow.
Avaira Vitality and other legacy lens lines
Avaira Vitality and CooperVision’s older replacement lens lines are classic cash cows: they serve a large installed base, so demand stays steady even when growth is slow. In fiscal 2025, The Cooper Companies reported about $4.0 billion in net sales, and these mature lenses need far less launch spending than new products. That makes them a reliable source of cash and margin support.
Proclear mature contact lens franchise
Proclear is a mature CooperVision franchise with more than 20 years in market, so it behaves like a cash cow in The Cooper Companies, Inc. BCG Matrix. It serves a slower-growth reusable lens segment and leans on repeat buys from an installed base rather than new-user growth.
That makes it a harvest asset: steady cash, limited upside, and modest reinvestment needs versus newer silicone hydrogel or daily lens lines. In FY2025, CooperCompanies kept the franchise as part of a portfolio that generated about $4 billion in annual sales.
- Long-life brand, repeat purchase model
- Slower growth, strong cash generation
- Best suited for harvest, not expansion
CooperSurgical office-based gynecology products
CooperSurgical office-based gynecology products, including uterine manipulators and retractors, sit in a mature, low-growth niche with steady procedure demand and sticky hospital relationships. They are cash cows because repeat use in routine gynecology helps support stable margin and cash flow across the surgical portfolio. The category’s role is less about rapid growth and more about dependable sales tied to recurring clinical workflows.
- Steady procedural demand
- Mature, limited-growth category
- Sticky hospital relationships
- Supports surgical cash flow
Cooper Companies’ Cash Cows: Steady Revenue Engines
Cash Cows in The Cooper Companies, Inc. are mature, repeat-buy businesses like Biofinity, Proclear, PARAGARD, and office-based gynecology tools. In FY2025, The Cooper Companies, Inc. reported about $4.0 billion in net sales, so these lines help fund the portfolio with steady cash, not fast growth. They fit a low-growth, high-cash BCG profile.
| Asset | Role | FY2025 |
|---|---|---|
| Biofinity | Cash cow | Repeat demand |
| PARAGARD | Cash cow | 10-year use |
Preview the Actual Deliverable
The Cooper Companies, Inc. Reference Sources
The preview you’re viewing is the exact The Cooper Companies, Inc. BCG Matrix document you’ll receive after purchase. No watered-down sample, no hidden pages—just the complete, professionally formatted file. Once purchased, it’s ready for immediate download and use. What you see here is what you get.
Dogs
Low-volume legacy surgical instruments
In FY2025, low-volume legacy surgical instruments in The Cooper Companies, Inc. stayed in fragmented, low-growth niches, with small share and weak pricing power. They can add operating cost without much growth, so they fit the Dogs box. The key signal is a product line that consumes effort but rarely scales.
Small non-core closure devices
Small non-core closure devices fit the Dogs quadrant because closure accessories are commoditized, price-led, and crowded, so brand power is weak and growth is slow. In The Cooper Companies, Inc.'s fiscal 2025, CooperSurgical revenue was about $1.4 billion, but this niche is likely a low-share, low-growth slice of that base. That profile points more to break-even cash use than to expansion.
Regional niche office products
CooperSurgical’s regional niche office products sit in the Dogs quadrant: narrow geography, low scale, and weak share make them hard to defend. Cooper Companies generated about $4 billion in fiscal 2025 sales, but these small office lines still face limited local demand and thin room for heavy investment. With low growth and low share, they fit classic value traps unless Cooper cuts cost or exits.
Older contact lens SKUs with declining demand
Older contact lens SKUs at The Cooper Companies, Inc. fit Dogs: daily disposables and premium silicone hydrogel lenses keep taking share, and legacy volume can fade as buyers trade up. In fiscal 2025, CooperVision still had to defend a mature portfolio while its growth leaned more on premium lines, so weak SKUs have little clear runway. Without a reset or exit plan, these aging lenses stay low-share, low-growth assets.
- Daily disposables keep winning share.
- Premium silicone hydrogel lenses displace legacy SKUs.
- Weak growth path signals Dog status.
Non-strategic diagnostic accessories
Non-strategic diagnostic accessories fit the Dog box: they sit outside The Cooper Companies, Inc.'s fertility core and do not match the scale of CooperVision or CooperSurgical. In FY2025, Cooper Companies generated about $4.1 billion in revenue, but the main value still came from core reproductive and vision lines, not small add-ons.
- Low share, low growth.
- Weak fit versus core franchises.
- Limited scale and pricing power.
Cooper Companies’ Legacy Dogs: Small, Slow, and Hard to Defend
In FY2025, Cooper Companies'" Dogs were small legacy lines with low share, weak pricing power, and little growth. They consumed operating effort but added limited scale, so they stayed value traps unless cut or exited. Cooper Companies reported about $4.1 billion in sales, but these niches were minor slices of that base.
| Dog area | FY2025 signal |
|---|---|
| Legacy surgical, closure, office, old lens SKUs | Low share, low growth, weak pricing power |
Question Marks
Preimplantation genetic testing and reproductive genomics
CooperSurgical's genomics arm sits in a fast-growing IVF niche, but it is still less entrenched than Cooper's core contact lenses or PARAGARD. PGT adoption keeps rising as clinics bundle embryo testing with IVF workflows, so the unit can gain share if it wins more lab and clinic contracts. That makes it a BCG Question Mark: high growth, but not yet a dominant position.
Embryo cryopreservation and lab automation expansion
Embryo cryopreservation and lab automation fit Question Marks because IVF labs are still standardizing workflows, even as demand keeps growing at roughly high-single-digit rates. CooperSurgical must keep funding equipment, software, and field sales to win share, since lab tools often need long validation cycles and heavy upfront capex. The category is attractive, but its competitive position is still being built.
Myopia management outside core markets
Myopia care is growing fast outside CooperVision's core markets, with Asia-Pacific carrying the heaviest load: China alone had about 600 million people with myopia, and U.S. demand is still small versus that base. Cooper Companies reported about $3.9 billion in fiscal 2025 revenue, with CooperVision near $2.4 billion, so even modest share gains in Europe and Asia can move the needle. Early wins in orthokeratology and soft myopia-control lenses make these markets look like future Stars if rollout keeps widening.
Premium new daily disposable launches
Premium new daily disposable launches can be a Question Mark for The Cooper Companies, Inc. because they can scale fast if eye-care practitioners adopt them, but launch share starts small against entrenched rivals. FY2025 sales still showed CooperVision depends on broad lens mix, so new premium SKUs need time, trials, and trade spend before they can turn into cash engines.
- Fast uptake needs practitioner buy-in
- Early share usually stays modest
- Heavy promotion is still required
That makes the category high-growth but capital-hungry, which fits a classic BCG Question Mark.
Digital fertility workflow and AI-enabled lab tools
Digital fertility workflows and AI lab tools are still early, but the prize is big: the U.S. saw 432,641 ART cycles and 95,860 live births in 2022, showing a large base for software-led gains. If CooperSurgical scales its workflow and data tools across clinics, this Question Mark can gain share fast and move toward Star status.
- Early adoption, high upside
- Clinic workflows are going digital
- Scale can lift share and margins
CooperSurgical's Fertility Bets Are Growing Question Marks
CooperSurgical's genomics, IVF lab tools, and digital fertility software are Question Marks: IVF demand is rising, but share is still building. With Cooper Companies at about $3.9 billion FY2025 revenue and CooperVision near $2.4 billion, these units can matter if they win more clinic contracts.
| Question Mark | Signal | FY2025 base |
|---|---|---|
| IVF genomics | High growth, low share | ART demand up |
| Lab automation | Capex-heavy rollout | Clinic adoption rising |
| Digital fertility | Early but scalable | U.S. 432,641 ART cycles |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.